Advanced search
Publication Cover
Expert Opinion on Emerging Drugs Volume 12, 2007 - Issue 1
Submit an article Journal homepage
151
Views
11
CrossRef citations to date
0
Altmetric
Review

Emerging therapeutic options for Philadelphia-positive acute lymphocytic leukemia

Yesid Alvarado Leukemia Fellow, Departments of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
,
Effrosyni Apostolidou Research Postdoctoral Fellow, Departments of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas, USA
,
Ronan Swords Hematology Fellow, Department of Hematology, University College Hospital, Galway, Ireland
&
Francis J Giles Professor of Medicine, Section of Developmental Therapeutics, Box 428, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas, 77030, USA. [email protected]
Pages 165-179 | Published online: 14 Mar 2007

Bibliography

  • GOKBUGET N, HOELZER D: Recent approaches in acute lymphoblastic leukemia in adults. Rev. Clin. Exp. Hematol. (2002) 6(2):114-141.
  • WESTBROOK CA, HOOBERMAN AL, SPINO C et al.: Clinical significance of the BCR-ABL fusion gene in adult acute lymphoblastic leukemia: a Cancer and Leukemia Group B Study (8762). Blood (1992) 80(12):2983-2990.
  • HOELZER D, THIEL E, LOFFLER H et al.: Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood (1988) 71(1):123-131.
  • COPLAND M, HAMILTON A, ELRICK LJ et al.: Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood (2006) 107(11):4532-4539.
  • VERMA A, STOCK W: Management of adult acute lymphoblastic leukemia: moving toward a risk-adapted approach. Curr. Opin. Oncol. (2001) 13(1):14-20.
  • DEANE M, KOH M, FORONI L et al.: FLAG-idarubicin and allogeneic stem cell transplantation for Ph-positive ALL beyond first remission. Bone Marrow Transplant (1998) 22(12):1137-1143.
  • HERZIG RH, BORTIN MM, BARRETT AJ et al.: Bone-marrow transplantation in high-risk acute lymphoblastic leukaemia in first and second remission. Lancet (1987) 1(8536):786-789.
  • NOWELL PC, HUNGERFORD DA: Chromosome studies on normal and leukemic human leukocytes. J. Natl Cancer Inst. (1960) 25:85-109.
  • ROWLEY JD: Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature (1973) 243(5405):290-293.
  • RIBEIRO RC, ABROMOWITCH M, RAIMONDI SC, MURPHY SB, BEHM F, WILLIAMS DL: Clinical and biologic hallmarks of the Philadelphia chromosome in childhood acute lymphoblastic leukemia. Blood (1987) 70(4):948-953.
  • RUSSO C, CARROLL A, KOHLER S et al.: Philadelphia chromosome and monosomy 7 in childhood acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood (1991) 77(5):1050-1056.
  • BLOOMFIELD CD, GOLDMAN AI, ALIMENA G et al.: Chromosomal abnormalities identify high-risk and low-risk patients with acute lymphoblastic leukemia. Blood (1986) 67(2):415-420.
  • WETZLER M, DODGE RK, MROZEK K et al.: PROSPECTIVE KARYOTYPE ANALYSIS IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA: the cancer and leukemia Group B experience. Blood (1999) 93(11):3983-3993.
  • GAYNOR J, CHAPMAN D, LITTLE C et al.: A cause-specific hazard rate analysis of prognostic factors among 199 adults with acute lymphoblastic leukemia: the Memorial Hospital experience since 1969. J. Clin. Oncol. (1988) 6(6):1014-1030.
  • FADERL S, KANTARJIAN HM, THOMAS DA et al.: Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Leuk. Lymphoma (2000) 36(3-4):263-273.
  • THOMAS X, DANAILA C, LE QH et al.: Long-term follow-up of patients with newly diagnosed adult acute lymphoblastic leukemia: a single institution experience of 378 consecutive patients over a 21-year period. Leukemia (2001) 15(12):1811-1822.
  • SECKER-WALKER LM, PRENTICE HG, DURRANT J, RICHARDS S, HALL E, HARRISON G: Cytogenetics adds independent prognostic information in adults with acute lymphoblastic leukaemia on MRC trial UKALL XA. MRC Adult Leukaemia Working Party. Br. J. Haematol. (1997) 96(3):601-610.
  • ANNINO L, VEGNA ML, CAMERA A et al.: Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. Blood (2002) 99(3):863-871.
  • FADERL S, TALPAZ M, ESTROV Z, O’BRIEN S, KURZROCK R, KANTARJIAN HM: The biology of chronic myeloid leukemia. N. Engl. J. Med. (1999) 341(3):164-172.
  • GARCIA-MANERO G, THOMAS DA: Salvage therapy for refractory or relapsed acute lymphocytic leukemia. Hematol. Oncol. Clin North Am (2001) 15(1):163-205.
  • KOLLER CA, KANTARJIAN HM, THOMAS D et al.: The hyper-CVAD regimen improves outcome in relapsed acute lymphoblastic leukemia. Leukemia (1997) 11(12):2039-2044.
  • AGUAYO A, CORTES J, THOMAS D, PIERCE S, KEATING M, KANTARJIAN H: Combination therapy with methotrexate, vincristine, polyethylene-glycol conjugated-asparaginase, and prednisone in the treatment of patients with refractory or recurrent acute lymphoblastic leukemia. Cancer (1999) 86(7):1203-1209.
  • SUKI S, KANTARJIAN H, GANDHI V et al.: Fludarabine and cytosine arabinoside in the treatment of refractory or relapsed acute lymphocytic leukemia. Cancer (1993) 72(7):2155-2160.
  • KANTARJIAN H, GANDHI V, CORTES J et al.: Phase II clinical and pharmacologic study of clofarabine in patients with refractory or relapsed acute leukemia. Blood (2003) 102(7):2379-2386.
  • BERG SL, BLANEY SM, DEVIDAS M et al.: Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children’s Oncology Group. J. Clin. Oncol. (2005) 23(15):3376-3382.
  • LARSON RA, DODGE RK, BURNS CP et al.: A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood (1995) 85(8):2025-2037.
  • SCHAISON G, SOMMELET D, BANCILLON A et al.: Treatment of acute lymphoblastic leukemia French protocol Fralle 83-87. Leukemia (1992) 6(Suppl. 2):148-152.
  • LINKER CA, LEVITT LJ, O’DONNELL M, FORMAN SJ, RIES CA: Treatment of adult acute lymphoblastic leukemia with intensive cyclical chemotherapy: a follow-up report. Blood (1991) 78(11):2814-2822.
  • NAGURA E, KIMURA K, YAMADA K et al.: Nation-wide randomized comparative study of doxorubicin, vincristine and prednisolone combination therapy with and without L-asparaginase for adult acute lymphoblastic leukemia. Cancer Chemother. Pharmacol. (1994) 33(5):359-365.
  • DELANNOY A, DELABESSE E, LHERITIER V et al.: Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 study. Leukemia (2006) 20(9):1526-1532.
  • DONATO NJ, WU JY, STAPLEY J et al.: Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res. (2004) 64(2):672-677.
  • CASSILETH PA, HARRINGTON DP, HINES JD et al.: Maintenance chemotherapy prolongs remission duration in adult acute nonlymphocytic leukemia. J. Clin. Oncol. (1988) 6(4):583-587.
  • DRUKER BJ, TALPAZ M, RESTA DJ et al.: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. (2001) 344(14):1031-1037.
  • O’BRIEN SG, GUILHOT F, LARSON RA et al.: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N. Engl. J. Med. (2003) 348(11):994-1004.
  • HUGHES TP, KAEDA J, BRANFORD S et al.: Frequency of major molecular responses to imatinib or interferon α plus cytarabine in newly diagnosed chronic myeloid leukemia. N. Engl. J. Med. (2003) 349(15):1423-1432.
  • DRUKER BJ, SAWYERS CL, KANTARJIAN H et al.: Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. (2001) 344(14):1038-1042.
  • OTTMANN OG, DRUKER BJ, SAWYERS CL et al.: A Phase II study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood (2002) 100(6):1965-1971.
  • YANADA M, TAKEUCHI J, SUGIURA I et al.: High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a Phase II study by the Japan Adult Leukemia Study Group. J. Clin. Oncol. (2006) 24(3):460-466.
  • OTTMANN OG, WASSMANN B: Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Hematology Am. Soc. Hematol. Educ. Program (2005):118-122.
  • PFEIFER H, OTTMANN OG, GOEKBUGET N et al.: A randomized Phase II study of single-agent imatinib versus chemotherapy therapy in elderly patients with philadelphia-positive acute lymphoblastic leukemia (Ph+ALL) including analysis of resistance patterns. Blood (2005) 106(11): Abstract 1824.
  • VIGNETTI M, FAZI P, MELONI G et al.: Dramatic improvement in CR rate and CR duration with imatinib in adult and elderly Ph+ all patients: results of the GIMEMA prospective study LAL0201. Blood (2004) 104(11): Abstract 2739.
  • DE LABARTHE A, ROUSSELOT P, HUGUET-RIGAL F et al.: Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia – results of the GRAAPH-2003 study. Blood (2007) 109(4):1408-1413.
  • THOMAS DA, FADERL S, CORTES J et al.: Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood (2004) 103(12):4396-407.
  • THOMAS DA, FADERL S, CORTES J et al.: Outcome with the Hyper-CVAD and Imatinib Mesylate Regimen in Philadelphia (Ph) Positive Acute Lymphocytic Leukemia (ALL). Blood (2005) 106(11): Abstract 1830.
  • LEE S, KIM YJ, MIN CK et al.: The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood (2005) 105(9):3449-3457.
  • LEE KH, LEE JH, CHOI SJ et al.: Clinical effect of imatinib added to intensive combination chemotherapy for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Leukemia (2005) 19(9):1509-1516.
  • SHAH NP, NICOLL JM, NAGAR B et al.: Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell (2002) 2(2):117-125.
  • NAGAR B, BORNMANN WG, PELLICENA P et al.: Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571). Cancer Res. (2002) 62(15):4236-4243.
  • HOCHHAUS A, LA ROSEE P: Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance. Leukemia (2004) 18(8):1321-1331.
  • CORBIN AS, DEMEHRI S, GRISWOLD IJ et al.: In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit. Blood (2005) 106(1):227-234.
  • COWAN-JACOB SW, GUEZ V, FENDRICH G et al.: Imatinib (STI571) resistance in chronic myelogenous leukemia: molecular basis of the underlying mechanisms and potential strategies for treatment. Mini Rev. Med. Chem. (2004) 4(3):285-299.
  • GRAFONE T, MANCINI M, OTTAVIANI E et al.: A novel 4-anilino-3-quinolinecarbonitrile dual Src and Abl kinase inhibitor (SKI-606) has in vitro activity on CML Ph+ blast cells resistant to imatinib. Proc. Am. Assoc. Cancer Res. (2005) 46:1408, Abstr. 5984.
  • BRANFORD S, RUDZKI Z, WALSH S et al.: Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood (2003) 102(1):276-283.
  • O’HARE T, WALTERS DK, DEININGER MW, DRUKER BJ: AMN107: tightening the grip of imatinib. Cancer Cell (2005) 7(2):117-119.
  • CARTER TA, WODICKA LM, SHAH NP et al.: Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc. Natl. Acad. Sci. USA (2005) 102(31):11011-11016.
  • HOCHHAUS A, KREIL S, CORBIN A et al.: Roots of clinical resistance to STI-571 cancer therapy. Science (2001) 293(5538):2163.
  • JABBOUR E, CORTES J, KANTARJIAN H: Novel tyrosine kinase inhibitors in chronic myelogenous leukemia. Curr. Opin. Oncol. (2006) 18(6):578-583.
  • TANIS KQ, VEACH D, DUEWEL HS, BORNMANN WG, KOLESKE AJP: Two distinct phosphorylation pathways have additive effects on Abl family kinase activation. Mol. Cell. Biol. (2003) 23(11):3884-3896.
  • WEISBERG E, GRIFFIN JD: Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood (2000) 95(11):3498-505.
  • VAN DEN HEUVEL-EIBRINK MM, SONNEVELD P, PIETERS R: The prognostic significance of membrane transport-associated multidrug resistance (MDR) proteins in leukemia. Int. J. Clin. Pharmacol. Ther. (2000) 38(3):94-110.
  • GALIMBERTI S, CERVETTI G, GUERRINI F et al.: Quantitative molecular monitoring of BCR-ABL and MDR1 transcripts in patients with chronic myeloid leukemia during Imatinib treatment. Cancer Genet. Cytogenet. (2005) 162(1):57-62.
  • MAHON FX, BELLOC F, LAGARDE V et al.: MDR1 gene overexpression confers resistance to imatinib mesylate in leukemia cell line models. Blood (2003) 101(6):2368-2373.
  • ABRAM CL, COURTNEIDGE SA: Src family tyrosine kinases and growth factor signaling. Exp. Cell Res. (2000) 254(1):1-13.
  • KLEJMAN A, SCHREINER SJ, NIEBOROWSKA-SKORSKA M et al.: The Src family kinase Hck couples BCR/ABL to STAT5 activation in myeloid leukemia cells. EMBO J. (2002) 21(21):5766-5774.
  • WEISBERG E, MANLEY PW, BREITENSTEIN W et al.: Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell (2005) 7(2):129-141.
  • BRADEEN HA, EIDE CA, O’HARE T et al.: Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood (2006) 108(7):2332-2338.
  • WEISBERG E, MANLEY P, MESTAN J, COWAN-JACOB S, RAY A, GRIFFIN JD: AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL. Br. J. Cancer (2006) 94(12):1765-1769.
  • KANTARJIAN H, GILES F, WUNDERLE L et al.: Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N. Engl. J. Med. (2006) 354(24):2542-2551.
  • ALVAREZ RH, KANTARJIAN HM, CORTES JE: The role of Src in solid and hematologic malignancies: development of new-generation Src inhibitors. Cancer (2006) 107(8):1918-1929.
  • GILES F, KANTARJIAN H, LARSON R et al.: A Phase I study of Talvesta (Talotrexin) in relapsed or refractory leukemia or myelodysplastic syndrome. American Society of Hematology Abstracts (2006) Abstr. 1968.
  • LOMBARDO LJ, LEE FY, CHEN P et al.: Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J. Med. Chem. (2004) 47(27):6658-6661.
  • DONATO NJ, WU JY, STAPLEY J et al.: BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571. Blood (2003) 101(2):690-698.
  • SHAH NP, TRAN C, LEE FY, CHEN P, NORRIS D, SAWYERS CL: Overriding imatinib resistance with a novel ABL kinase inhibitor. Science (2004) 305(5682):399-401.
  • BURGESS MR, SKAGGS BJ, SHAH NP, LEE FY, SAWYERS CL: Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance. Proc. Natl Acad. Sci. USA (2005) 102(9):3395-3400.
  • AZAM M, LATEK RR, DALEY GQ: Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell (2003) 112(6):831-843.
  • TALPAZ M, SHAH NP, KANTARJIAN H et al.: Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. N. Engl. J. Med. (2006) 354(24):2531-2541.
  • HOCHHAUS A, KANTARJIAN H, BACCARANI M, JONES F: Dasatinib efficacy and safety in patients with chronic phase cml resistant or intolerable to imatinib: results of the CA180013 ‘START C’ Phase II study. J. Clin. Oncol. (2006) 24:339s Abstr. 6508.
  • TALPAZ M, APPERLY J, KIM D, JONES F: Dasatinib phase II study in patients with accelerated phase CML who are resistant or intolerant to imatinib: results of the CA180005 "START-A" study (abstract 6526). J. Clin. Oncol. (2006) 24:343s.
  • CORTES J, KIM J, ROSTI P, JONES F: Dasatinib in patients with CML myeloid blast crisis who are imatinib resistant or intolerant: results of the CA180006 "START-B" study (abstract 6529). J. Clin. Oncol. (2006) 24:344s.
  • ATALLAH E, KANTARJIAN H, DE LIMA M et al.: The Role of dasatinib in patients with Philadelphia (Ph) positive acute lymphocytic leukemia (ALL) and chronic myeloid leukemia (CML) relapsing after stem cell transplantation (SCT). ASH Annual Meeting Abstracts (2006) 108(11):4520.
  • GOLAS JM, ARNDT K, ETIENNE C et al.: SKI-606, a 4-anilino-3- quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res. (2003) 63(2):375-381.
  • BOSCHELLI DH, WU B, BARRIOS SOSA AC et al.: Synthesis and Src kinase inhibitory activity of 2-phenyl- and 2-thienyl-7-phenylaminothieno[3,2-b]pyridine-6-carbonitriles. J. Med. Chem. (2005) 48(11):3891-902.
  • KIMURA S, NAITO H, SEGAWA H et al.: NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia. Blood (2005) 106(12):3948-3954.
  • NAITO H, KIMURA S, NAKAYA Y et al.: In vivo antiproliferative effect of NS-187, a dual Bcr-Abl/Lyn tyrosine kinase inhibitor, on leukemic cells harbouring Abl kinase domain mutations. Leuk. Res. (2006) 30(11):1443-1446.
  • KIMURA S, NIWA T, HIRABAYASHI K, MAEKAWA T: Development of NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor. Cancer Chemother. Pharmacol. (2006) 58(Suppl. 7):55-61.
  • MATTHEWS N, VISINTIN C, HARTZOULAKIS B, JARVIS A, SELWOOD DL: Aurora A and B kinases as targets for cancer: will they be selective for tumors? Expert Rev. Anti-Cancer Ther. (2006) 6(1):109-120.
  • HARRINGTON EA, BEBBINGTON D, MOORE J et al.: VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat. Med. (2004) 10(3):262-267.
  • SAMANTA AK, LIN H, SUN T, KANTARJIAN H, ARLINGHAUS RB: Janus kinase 2: a critical target in chronic myelogenous leukemia. Cancer Res. (2006) 66(13):6468-6472.
  • GILES F, RIZZIERI DA, GEORGE S et al.: A Phase I study of Talvesta (Talotrexin) in relapsed or refractory leukemia or myelodysplastic syndrome. ASH Abstracts (2006):Abstract 1968.
  • YOUNG MA, SHAH NP, CHAO LH et al.: Structure of the kinase domain of an imatinib-resistant Abl mutant in complex with the Aurora kinase inhibitor VX-680. Cancer Res. (2006) 66(2):1007-1014.
  • DA SILVA CP, DE OLIVEIRA CR, DA CONCEICAO M, DE LIMA P: Apoptosis as a mechanism of cell death induced by different chemotherapeutic drugs in human leukemic T-lymphocytes. Biochem. Pharmacol. (1996) 51(10):1331-1340.
  • HARMON BV, TAKANO YS, WINTERFORD CM, POTTEN CS: Cell death induced by vincristine in the intestinal crypts of mice and in a human Burkitt’s lymphoma cell line. Cell Prolif. (1992) 25(6):523-536.
  • KOBAYASHI H, TAKEMURA Y, HOLLAND JF, OHNUMA T: Vincristine saturation of cellular binding sites and its cytotoxic activity in human lymphoblastic leukemia cells: mechanism of inoculum effect. Biochem. Pharmacol. (1998) 55(8):1229-1234.
  • HAIM N, EPELBAUM R, BEN-SHAHAR M, YARNITSKY D, SIMRI W, ROBINSON E: Full dose vincristine (without 2-mg dose limit) in the treatment of lymphomas. Cancer (1994) 73(10):2515-2519.
  • KRISHNA R, WEBB MS, ST ONGE G, MAYER LD: Liposomal and nonliposomal drug pharmacokinetics after administration of liposome-encapsulated vincristine and their contribution to drug tissue distribution properties. J. Pharmacol. Exp. Ther. (2001) 298(3):1206-1212.
  • GUTHLEIN F, BURGER AM, BRANDL M et al.: Pharmacokinetics and antitumor activity of vincristine entrapped in vesicular phospholipid gels. Anti-Cancer Drugs (2002) 13(8):797-805.
  • LEONETTI C, SCARSELLA M, SEMPLE SC et al.: In vivo administration of liposomal vincristine sensitizes drug-resistant human solid tumors. Int. J. Cancer (2004) 110(5):767-774.
  • WEBB MS, LOGAN P, KANTER PM et al.: Preclinical pharmacology, toxicology and efficacy of sphingomyelin/cholesterol liposomal vincristine for therapeutic treatment of cancer. Cancer Chemother. Pharmacol. (1998) 42(6):461-470.
  • WEBB MS, HARASYM TO, MASIN D, BALLY MB, MAYER LD: Sphingomyelin-cholesterol liposomes significantly enhance the pharmacokinetic and therapeutic properties of vincristine in murine and human tumour models. Br. J. Cancer (1995) 72(4):896-904.
  • BOMAN NL, TRON VA, BALLY MB, CULLIS PR: Vincristine-induced dermal toxicity is significantly reduced when the drug is given in liposomes. Cancer Chemother. Pharmacol. (1996) 37(4):351-355.
  • GELMON KA, TOLCHER A, DIAB AR et al.: Phase I study of liposomal vincristine. J. Clin. Oncol. (1999) 17(2):697-705.
  • RAVANDI F, JORGENSEN JL, O’BRIEN SM et al.: Eradication of minimal residual disease in hairy cell leukemia. Blood (2006) 107(12):4658-4662.
  • KANTARJIAN H, THOMAS D, O’BRIEN S et al.: Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer (2004) 101(12):2788-801.
  • DE VITA V, HELLMAN S, ROSENBERG S: Principles and Practices in Oncology, 4th Edn. Lippincott, Williams & Wilkins, Philadelphia (1993).
  • GANZINA F, PACCIARINI MA, DI PIETRO N: Idarubicin (4-demethoxydaunorubicin). A preliminary overview of preclinical and clinical studies. Invest. New Drugs (1986) 4(1):85-105.
  • LING YH, PRIEBE W, YANG LY, BURKE TG, POMMIER Y, PEREZ-SOLER R: In vitro cytotoxicity, cellular pharmacology, and DNA lesions induced by annamycin, an anthracycline derivative with high affinity for lipid membranes. Cancer Res. (1993) 53(7):1583-1589.
  • PEREZ-SOLER R, PRIEBE W: Anthracycline antibiotics with high liposome entrapment: structural features and biological activity. Cancer Res. (1990) 50(14):4260-4266.
  • HORTON D, PRIEBE W: Oxyhalogenation of glycals for the synthesis of anti-tumor-active 2’-halo daunorubicin analogs. Carbohydr. Res. (1985) 136:391-396.
  • ZOU Y, LING YH, VAN NT, PRIEBE W, PEREZ-SOLER R: Antitumor activity of free and liposome-entrapped annamycin, a lipophilic anthracycline antibiotic with non-cross-resistance properties. Cancer Res. (1994) 54(6):1479-1484.
  • ANDREEF M, GILES F, KORNBLAU S et al.: Phase I study of annamycin, a novel anthracycline, in patients with relapsed/refractory acute myeloid leukemia and lymphoid leukemias. Proc. Am. Soc. Clin. Oncol. (2001) 20:Abstr. 1211.
  • SHIH C, CHEN VJ, GOSSETT LS et al.: LY231514, a pyrrolo[2,3-d]pyrimidine-based antifolate that inhibits multiple folate-requiring enzymes. Cancer Res. (1997) 57(6):1116-1123.
  • GIBBS D, JACKMAN A: Pemetrexed disodium. Nat. Rev. Drug Discov (2005) Suppl.:S16-S17.
  • LOKIEC F: [Pemetrexed: new multitargeted antimetabolite]. Rev. Pneumol. Clin. (2005) 61(4 Pt 2):4S5-4S7.
  • TONKINSON JL, MARDER P, ANDIS SL et al.: Cell cycle effects of antifolate antimetabolites: implications for cytotoxicity and cytostasis. Cancer Chemother. Pharmacol. (1997) 39(6):521-531.
  • EISMANN U, OBERSCHMIDT O, EHNERT M et al.: Pemetrexed: mRNA expression of the target genes TS, GARFT and DHFR correlates with the in vitro chemosensitivity of human solid tumors. Int. J. Clin. Pharmacol. Ther. (2005) 43(12):567-569.
  • CHATTOPADHYAY S, ZHAO R, KRUPENKO SA, KRUPENKO N, GOLDMAN ID: The inverse relationship between reduced folate carrier function and pemetrexed activity in a human colon cancer cell line. Mol. Cancer Ther. (2006) 5(2):438-449.
  • FAESSEL HM, SLOCUM HK, JACKSON RC et al.: Super in vitro synergy between inhibitors of dihydrofolate reductase and inhibitors of other folate-requiring enzymes: the critical role of polyglutamylation. Cancer Res. (1998) 58(14):3036-3050.
  • SCAGLIOTTI GV, NOVELLO S: Pemetrexed and its emerging role in the treatment of thoracic malignancies. Expert Opin. Investig. Drugs (2003) 12(5):853-863.
  • CLARKE SJ, BOYER MJ, MILLWARD M et al.: A Phase I/II study of pemetrexed and vinorelbine in patients with non-small cell lung cancer. Lung Cancer (2005) 49(3):401-412.
  • NIYIKIZA C, BAKER SD, SEITZ DE et al.: Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol. Cancer Ther. (2002) 1(7):545-552.
  • ROSOWSKY A: PT523 and other aminopterin analogs with a hemiphthaloyl-L-ornithine side chain: exceptionally tight-binding inhibitors of dihydrofolate reductase which are transported by the reduced folate carrier but cannot form polyglutamates. Curr Med Chem (1999) 6(4):329-352.
  • CHEN G, WRIGHT JE, ROSOWSKY A: Dihydrofolate reductase binding and cellular uptake of nonpolyglutamatable antifolates: correlates of cytotoxicity toward methotrexate-sensitive and -resistant human head and neck squamous carcinoma cells. Mol. Pharmacol. (1995) 48(4):758-765.
  • RHEE MS, GALIVAN J, TYOBEKA EM, SHERMAN ML, ROSOWSKY A: Effect of a novel antifolate, N-α-(4-amino-4-deoxypteroyl)-N-δ-hemiphthaloyll-l-ornithine (PT523), on growth of H35 rat hepatoma and HEPG2 human hepatoma cells. Adv. Exp. Med. Biol. (1993) 338:461-464.
  • ZHAO R, GAO F, GOLDMAN ID: Marked suppression of the activity of some, but not all, antifolate compounds by augmentation of folate cofactor pools within tumor cells. Biochem. Pharmacol. (2001) 61(7):857-865.
  • ROWINSKY EK, DONEHOWER RC: The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics. Pharmacol. Ther. (1991) 52(1):35-84.
  • DISTEFANO M, SCAMBIA G, FERLINI C et al.: Anti-proliferative activity of a new class of taxanes (14beta-hydroxy-10-deacetylbaccatin III derivatives) on multidrug-resistance-positive human cancer cells. Int. J. Cancer (1997) 72(5):844-850.
  • STARETZ ME, HASTIE SB: Synthesis and tubulin binding of novel C-10 analogues of colchicine. J. Med. Chem. (1993) 36(6):758-764.
  • ROWINSKY EK: The development and clinical utility of the taxane class of antimicrotubule chemotherapy agents. Ann. Rev Med (1997) 48:353-374.
  • TOZER GM, KANTHOU C, PARKINS CS, HILL SA: The biology of the combretastatins as tumour vascular targeting agents. Int. J. Exp. Pathol. (2002) 83(1):21-38.
  • SZCZEPANKIEWICZ BG, LIU G, JAE HS et al.: New antimitotic agents with activity in multi-drug-resistant cell lines and in vivo efficacy in murine tumor models. J. Med. Chem. (2001) 44(25):4416-4430.
  • GWALTNEY SL II, IMADE HM, LI Q et al.: Novel sulfonate derivatives: potent antimitotic agents. Bioorg. Med. Chem. Lett (2001) 11(13):1671-1673.
  • SEGRETI JA, POLAKOWSKI JS, KOCH KA: Tumor selective antivascular effects of the novel antimitotic compound ABT-751: an in vivo rat regional hemodynamic study. Cancer Chemother. Pharmacol. (2004) 54(3):273-281.
  • BAGULEY BC, HOLDAWAY KM, THOMSEN LL, ZHUANG L, ZWI LJ: Inhibition of growth of colon 38 adenocarcinoma by vinblastine and colchicine: evidence for a vascular mechanism. Eur. J. Cancer (1991) 27(4):482-487.
  • FUNAHASHI Y, KOYANAGI N, KITOH K: Effect of E7010 on liver metastasis and life span of syngeneic C57BL/6 mice bearing orthotopically transplanted murine Colon 38 tumor. Cancer Chemother. Pharmacol. (2001) 47(2):179-184.
  • KOYANAGI N, NAGASU T, FUJITA F et al.: In vivo tumor growth inhibition produced by a novel sulfonamide, E7010, against rodent and human tumors. Cancer Res. (1994) 54(7):1702-1706.
  • IWAMOTO Y, NISHIO K, FUKUMOTO H, YOSHIMATSU K, YAMAKIDO M, SAIJO N: Preferential binding of E7010 to murine β-3-tubulin and decreased beta 3-tubulin in E7010-resistant cell lines. Jpn. J. Cancer Res. (1998) 89(9):954-962.
  • OWA T, YOKOI A, YAMAZAKI K, YOSHIMATSU K, YAMORI T, NAGASU T: Array-based structure and gene expression relationship study of antitumor sulfonamides including N-[2-[(4-hydroxyphenyl)amino]-3-pyridinyl]-4-methoxybenzenesulfonamide and N-(3-chloro-7-indolyl)-1,4-benzenedisulfonamide. J. Med. Chem. (2002) 45(22):4913-4922.
  • SPRAGUE E, FLEMING GF, CARR R et al.: Phase I study of 21-day continuous dosing of the oral antimitotic agent ABT-751. Proc. Am. Soc. Clin. Oncol. (2003) 22:Abstr. 518.
  • YEE KW, HAGEY A, VERSTOVSEK S et al.: Phase I study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies. Clin. Cancer Res. (2005) 11(18):6615-6624.
  • NOGALES E, WOLF SG, DOWNING KH: Structure of the αβ tubulin dimer by electron crystallography. Nature (1998) 391(6663):199-203.
  • UPPULURI S, KNIPLING L, SACKETT DL, WOLFF J: Localization of the colchicine-binding site of tubulin. Proc. Natl Acad. Sci. USA (1993) 90(24):11598-11602.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.